Catatonia

Last updated

Catatonia
Other namesCatatonic syndrome
Satatonic stupor3.jpg
A patient in catatonic stupor
Specialty Psychiatry, neurology
Symptoms Immobility, mutism, staring, posturing, rigidity, low consciousness, etc.
Complications Physical trauma, malignant catatonia (autonomic instability, life-threatening), dehydration, pneumonia, pressure ulcers due to immobility, muscle contractions, deep vein thrombosis (DVT) [1] and pulmonary embolism (PE) [1]
CausesUnderlying illness (psychiatric, neurologic, or medical), brain injury/damage, certain drugs/medications
Diagnostic method Clinical, Lorazepam challenge
TreatmentBenzodiazepines (lorazepam challenge), electroconvulsive therapy (ECT) [1]

Catatonia is a complex neuropsychiatric behavioral syndrome that is characterized by abnormal movements, immobility, abnormal behaviors, and withdrawal. [2] [3] The onset of catatonia can be acute or subtle and symptoms can wax, wane, or change during episodes. It has historically been related to schizophrenia (catatonic schizophrenia), but catatonia is most often seen in mood disorders. [3] It is now known that catatonic symptoms are nonspecific and may be observed in other mental, neurological, and medical conditions. Catatonia is now a stand-alone diagnosis (although some experts disagree), and the term is used to describe a feature of the underlying disorder. [4]

Contents

There are several subtypes of catatonia: akinetic catatonia, excited catatonia, malignant catatonia, and delirious mania. [5]

Failure to recognize and treat catatonia may lead to poor outcomes and can be potentially fatal. Treatment with benzodiazepines or ECT can lead to remission of catatonia. [3] There is growing evidence of the effectiveness of the NMDA receptor antagonists amantadine and memantine for benzodiazepine-resistant catatonia. [6] Antipsychotics are sometimes employed, but they can worsen symptoms and have serious adverse effects. [7]

Signs and symptoms

The presenting signs of catatonia vary greatly and may be subtle or more markedly pronounced, and symptoms may develop over hours or days to weeks. [8]

Because most patients with catatonia have an underlying psychiatric illness, the majority will present with worsening depression, mania, or psychosis followed by catatonia symptoms. [3] Catatonia presents as a motor disturbance in which patients will display marked reduction in movement, marked agitation, or a mixture of both despite having the physical capacity to move normally. These patients may be unable to start an action or stop one. Movements and mannerisms may be repetitive, or purposeless. [3] [9]

The most common signs of catatonia are immobility, mutism, withdrawal and refusal to eat, staring, negativism, posturing (rigidity), rigidity, waxy flexibility/catalepsy, stereotypy (purposeless, repetitive movements), echolalia or echopraxia, verbigeration (repeat meaningless phrases). [10] It should not be assumed that patients presenting with catatonia are unaware of their surroundings as some patients can recall in detail their catatonic state and their actions. [10]

There are several subtypes of catatonia and they are characterized by the specific movement disturbance and associated features. Although catatonia can be divided into various subtypes, the natural history of catatonia is often fluctuant and different states can exist within the same individual. [11]

Subtypes

Withdrawn Catatonia: This form of catatonia is characterized by decreased response to external stimuli, immobility or inhibited movement, mutism, staring, posturing, and negativism. Patients may sit or stand in the same position for hours, may hold odd positions, and may resist movement of their extremities. [2] [3]

Excited Catatonia: Excited catatonia is characterized by odd mannerisms/gestures, performing purposeless or inappropriate actions, excessive motor activity, restlessness, stereotypy, impulsivity, agitation, and combativeness. Speech and actions may be repetitive or mimic another person's. [2] [3] [10] People in this state are extremely hyperactive and may have delusions and hallucinations. [12] Catatonic excitement is commonly cited as one of the most dangerous mental states in psychiatry.

Malignant Catatonia: Malignant catatonia is a life-threatening condition that may progress rapidly within a few days. It is characterized by fever, abnormalities in blood pressure, heart rate, respiratory rate, diaphoresis (sweating), and delirium. [2] [3] Certain lab findings are common with this presentation; however, they are nonspecific, which means that they are also present in other conditions and do not diagnose catatonia. These lab findings include: leukocytosis, elevated creatine kinase, low serum iron. The signs and symptoms of malignant catatonia overlap significantly with neuroleptic malignant syndrome (NMS) and so a careful history, review of medications, and physical exam are critical to properly differentiate these conditions. For example, if the patient has waxy flexibility and holds a position against gravity when passively moved into that position, then it is likely catatonia. If the patient has a "lead-pipe rigidity" then NMS should be the prime suspect.[ citation needed ]

Other forms:

Complications

Patients may experience several complications from being in a catatonic state. The nature of these complications will depend on the type of catatonia being experienced by the patient. For example, patients presenting with withdrawn catatonia may have refusal to eat which will in turn lead to malnutrition and dehydration. [17] Furthermore, if immobility is a symptom the patient is presenting with, then they may develop pressure ulcers, muscle contractions, and are at risk of developing deep vein thrombosis (DVT) and pulmonary embolus (PE). [17] Patients with excited catatonia may be aggressive and violent, and physical trauma may result from this. Catatonia may progress to the malignant type which will present with autonomic instability and may be life-threatening. Other complications also include the development of pneumonia and neuroleptic malignant syndrome. [3]

Causes

Catatonia is almost always secondary to another underlying illness, often a psychiatric disorder. Mood disorders such as a bipolar disorder and depression are the most common etiologies to progress to catatonia. [3] Other psychiatric associations include schizophrenia and other primary psychotic disorders. [7] It also is related to autism spectrum disorders and ADHD. [18] Psychodynamic theorists have interpreted catatonia as a defense against the potentially destructive consequences of responsibility, and the passivity of the disorder provides relief. [19]

Catatonia is also seen in many medical disorders, including infections (such as encephalitis), autoimmune disorders, [20] meningitis, focal neurological lesions (including strokes), [21] alcohol withdrawal, [22] abrupt or overly rapid benzodiazepine withdrawal, [23] [24] [25] cerebrovascular disease, neoplasms, head injury, [26] and some metabolic conditions (homocystinuria, diabetic ketoacidosis, hepatic encephalopathy, and hypercalcaemia). [26]

Pathogenesis

The pathophysiology that leads to catatonia is still poorly understood and a definite mechanism remains unknown. [10] [27] Neurologic studies have implicated several pathways; however, it remains unclear whether these findings are the cause or the consequence of the disorder. [28]

Abnormalities in GABA, glutamate signaling, serotonin, and dopamine transmission are believed to be implicated in catatonia. [3] [10] [29]

Furthermore, it has also been hypothesized that pathways that connect the basal ganglia with the cortex and thalamus is involved in the development of catatonia. [30]

Image from page 110 of "Mental medicine and nursing - for use in training-schools for nurses and in medical classes and a ready reference for the general practitioner" (1915).jpg
Image from page 219 of "A treatise on mental diseases" (1900).jpg
Image from page 719 of "Diseases of the nervous system - a text-book of neurology and psychiatry" (1915).jpg

Diagnosis

There is not yet a definitive consensus regarding diagnostic criteria of catatonia. In the fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5, 2013) and the World Health Organization's eleventh edition of the International Classification of Diseases ( ICD-11, 2022), the classification is more homogeneous than in earlier editions. Prominent researchers in the field have other suggestions for diagnostic criteria. [31]

DSM-5 classification

The DSM-5 does not classify catatonia as an independent disorder, but rather it classifies it as catatonia associated with another mental disorder, due to another medical condition, or as unspecified catatonia. [32] [33] :134–135

Catatonia is diagnosed by the presence of three or more of the following 12 psychomotor symptoms in association with a mental disorder, medical condition, or unspecified: [32] :135

Other disorders (additional code 293.89 [F06.1] to indicate the presence of the co-morbid catatonia):

If catatonic symptoms are present but do not form the catatonic syndrome, a medication- or substance-induced aetiology should first be considered. [34]

ICD-11 classification

In ICD-11 catatonia is defined as a syndrome of primarily psychomotor disturbances that is characterized by the simultaneous occurrence of several symptoms such as stupor; catalepsy; waxy flexibility; mutism; negativism; posturing; mannerisms; stereotypies; psychomotor agitation; grimacing; echolalia and echopraxia. Catatonia may occur in the context of specific mental disorders, including mood disorders, schizophrenia or other primary psychotic disorders, and Neurodevelopmental disorders, and may be induced by psychoactive substances, including medications. Catatonia may also be caused by a medical condition not classified under mental, behavioral, or neurodevelopmental disorders.

Assessment/Physical

Catatonia is often overlooked and under-diagnosed. [17] Patients with catatonia most commonly have an underlying psychiatric disorder, for this reason, physicians may overlook signs of catatonia due to the severity of the psychosis the patient is presenting with. Furthermore, the patient may not be presenting with the common signs of catatonia such as mutism and posturing. Additionally, the motor abnormalities seen in catatonia are also present in psychiatric disorders. For example, a patient with mania will show increased motor activity that may progress to exciting catatonia. One way in which physicians can differentiate between the two is to observe the motor abnormality. Patients with mania present with increased goal-directed activity. On the other hand, the increased activity in catatonia is not goal-directed and often repetitive. [3]

Catatonia is a clinical diagnosis and there is no specific laboratory test to diagnose it. However, certain testing can help determine what is causing the catatonia. An EEG will likely show diffuse slowing. If seizure activity is driving the syndrome, then an EEG would also be helpful in detecting this. CT or MRI will not show catatonia; however, they might reveal abnormalities that might be leading to the syndrome. Metabolic screens, inflammatory markers, or autoantibodies may reveal reversible medical causes of catatonia. [3]

Vital signs should be frequently monitored as catatonia can progress to malignant catatonia which is life-threatening. Malignant catatonia is characterized by fever, hypertension, tachycardia, and tachypnea. [3]

Rating scale

Various rating scales for catatonia have been developed, however, their utility for clinical care has not been well established. [35] The most commonly used scale is the Bush-Francis Catatonia Rating Scale (BFCRS) (external link is provided below). [36] The scale is composed of 23 items with the first 14 items being used as the screening tool. If 2 of the 14 are positive, this prompts for further evaluation and completion of the remaining 9 items.

A diagnosis can be supported by the lorazepam challenge [37] or the zolpidem challenge. [38] While proven useful in the past, barbiturates are no longer commonly used in psychiatry; thus the option of either benzodiazepines or ECT.

Differential diagnosis

The differential diagnosis of catatonia is extensive as signs and symptoms of catatonia may overlap significantly with those of other conditions. Therefore, a careful and detailed history, medication review, and physical exam are key to diagnosing catatonia and differentiating it from other conditions. Furthermore, some of these conditions can themselves lead to catatonia. The differential diagnosis is as follows:

Treatment

The initial treatment of catatonia is to stop medication that could be potentially leading to the syndrome. [37] These may include steroids, stimulants, anticonvulsants, neuroleptics or dopamine blockers. [3] A "lorazepam challenge", in which patients are given 2 mg of IV lorazepam (or another benzodiazepine) may aid in the diagnosis. [60] Most patients with catatonia will respond significantly to this within the first 15–30 minutes. If no change is observed during the first dose, then a second dose is given and the patient is re-examined. If the patient responds to the lorazepam challenge, then lorazepam can be scheduled at interval doses until the catatonia resolves. [3] The lorazepam must be tapered slowly, otherwise, the catatonia symptoms may return. The underlying cause of the catatonia should also be treated during this time. ECT may also be used to resolve catatonia. The success rate of ECT and lorazepam in the treatment of catatonia is estimated to be 60-100%, with earlier treatment being associated with a greater likelihood of treatment success. [8] ECT is usually administered as multiple sessions over one-two weeks and is usually successful in those in which lorazepam fails. [8] ECT in combination with benzodiazepines is used to treat malignant catatonia. In France, zolpidem has also been used in diagnosis, and response may occur within the same time period. Ultimately the underlying cause needs to be treated. [7]

Supportive care is required in those with catatonia. This includes monitoring vital signs and fluid status, and in those with chronic symptoms; maintaining nutrition and hydration, medications to prevent a blood clot, and measures to prevent the development of pressure ulcers. [8]

Electroconvulsive therapy (ECT) is an effective treatment for catatonia that is well acknowledged. [37] ECT has also shown favorable outcomes in patients with chronic catatonia. However, it has been pointed out that further high quality randomized controlled trials are needed to evaluate the efficacy, tolerance, and protocols of ECT in catatonia. [61]

Antipsychotics are sometimes used in those with a co-existing psychosis, however they should be used with care as they may worsen catatonia and have a risk of neuroleptic malignant syndrome, a dangerous condition that can mimic catatonia and requires immediate discontinuation of the antipsychotic. [7] [8]

There is evidence that clozapine works better than other antipsychotics to treat catatonia. [62] [8]

Excessive glutamate activity is believed to be involved in catatonia; [62] when first-line treatment options fail, NMDA antagonists such as amantadine or memantine may be used. Amantadine may have an increased incidence of tolerance with prolonged use and can cause psychosis, due to its additional effects on the dopamine system. Memantine has a more targeted pharmacological profile for the glutamate system, reduced incidence of psychosis and may therefore be preferred for individuals who cannot tolerate amantadine. Topiramate is another treatment option for resistant catatonia; it produces its therapeutic effects by producing glutamate antagonism via modulation of AMPA receptors. [6]

Prognosis

Twenty-five percent of psychiatric patients with catatonia will have more than one episode throughout their lives. [8] Treatment response for patients with catatonia is 50–70%, with treatment failure being associated with a poor prognosis. Many of these patients will require long-term and continuous mental health care. For patients with catatonia with underlying schizophrenia, the prognosis is much poorer. [3]

Epidemiology

Catatonia has been historically studied in psychiatric patients. [63] Catatonia is underrecognized and the features may be mistaken for other disorders (such as negative symptoms of schizophrenia), leading to an underestimate of the prevalence. The prevalence has been reported to be as high as 10% in those with acute psychiatric illnesses, and 9-30% in the setting of inpatient psychiatric care. [8] [64] [10] One large population estimate has suggested that the incidence of catatonia is 10.6 episodes per 100 000 person-years. [65] It occurs in males and females in approximately equal numbers. [66] [65] 21-46% of all catatonia cases can be attributed to a general medical condition. [17]

History

Reports of stupor-like and catatonia-like states abound in the history of psychiatry. [67] After the middle of the 19th century there was an increase of interest in the motor disorders accompanying madness, [68] culminating in the publication by Karl Ludwig Kahlbaum in 1874 of Die Katatonie oder das Spannungsirresein ("Catatonia or Tension Insanity"). [69]

See also

Related Research Articles

<span class="mw-page-title-main">Benzodiazepine</span> Class of depressant drugs

Benzodiazepines, colloquially called "benzos", are a class of depressant drugs whose core chemical structure is the fusion of a benzene ring and a diazepine ring. They are prescribed to treat conditions such as anxiety disorders, insomnia, and seizures. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955 and was made available in 1960 by Hoffmann–La Roche, who soon followed with diazepam (Valium) in 1963. By 1977, benzodiazepines were the most prescribed medications globally; the introduction of selective serotonin reuptake inhibitors (SSRIs), among other factors, decreased rates of prescription, but they remain frequently used worldwide.

Psychosis is a condition of the mind that results in difficulties determining what is real and what is not real. Symptoms may include delusions and hallucinations, among other features. Additional symptoms are incoherent speech and behavior that is inappropriate for a given situation. There may also be sleep problems, social withdrawal, lack of motivation, and difficulties carrying out daily activities. Psychosis can have serious adverse outcomes.

<span class="mw-page-title-main">Electroconvulsive therapy</span> Medical procedure in which electrical current is passed through the brain

Electroconvulsive therapy (ECT) or electroshock therapy (EST) is a psychiatric treatment where a generalized seizure is electrically induced to manage refractory mental disorders. Typically, 70 to 120 volts are applied externally to the patient's head, resulting in approximately 800 milliamperes of direct current passing between the electrodes, for a duration of 100 milliseconds to 6 seconds, either from temple to temple or from front to back of one side of the head. However, only about 1% of the electrical current crosses the bony skull into the brain because skull impedance is about 100 times higher than skin impedance.

<span class="mw-page-title-main">Mood disorder</span> Mental disorder affecting the mood of an individual, over a long period of time

A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and behavioral disorder where a disturbance in the person's mood is the main underlying feature. The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).

A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric settings, potentially involuntarily during commitment. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization, thereby lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries, and the reasons for the relapses are under research.

<span class="mw-page-title-main">Neuroleptic malignant syndrome</span> Medical condition

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening reaction that can occur in response to antipsychotic (neuroleptic) medications. Symptoms include high fever, confusion, rigid muscles, variable blood pressure, sweating, and fast heart rate. Complications may include rhabdomyolysis, high blood potassium, kidney failure, or seizures.

<span class="mw-page-title-main">Akathisia</span> Movement disorder involving a feeling of inner restlessness

Akathisia is a movement disorder characterized by a subjective feeling of inner restlessness accompanied by mental distress and an inability to sit still. Usually, the legs are most prominently affected. Those affected may fidget, rock back and forth, or pace, while some may just have an uneasy feeling in their body. The most severe cases may result in poor adherence to medications, exacerbation of psychiatric symptoms, and, because of this, aggression, violence, and/or suicidal thoughts. Akathisia is also associated with threatening behaviour and physical aggression in mentally disordered patients. However, the attempts to found potential links between akathisia and emerging suicidal or homicidal behaviour were not systematic and were mostly based on a limited number of case reports and small case series. Apart from these few low-quality studies, there is another more recent and better quality study that concludes «akathisia cannot be reliably linked to the presence of suicidal behaviour in patients treated with antipsychotic medication».

Schizoaffective disorder is a mental disorder characterized by abnormal thought processes and an unstable mood. This diagnosis requires symptoms of both schizophrenia and a mood disorder: either bipolar disorder or depression. The main criterion is the presence of psychotic symptoms for at least two weeks without any mood symptoms. Schizoaffective disorder can often be misdiagnosed when the correct diagnosis may be psychotic depression, bipolar I disorder, schizophreniform disorder, or schizophrenia. This is a problem as treatment and prognosis differ greatly for most of these diagnoses.

Disorganized schizophrenia, or hebephrenia, was a subtype of schizophrenia prior to 2013. Subtypes of schizophrenia were no longer recognized as separate conditions in the DSM 5, published in 2013. The disorder is no longer listed in the 11th revision of the International Classification of Diseases (ICD-11).

<span class="mw-page-title-main">Psychotic depression</span> Medical condition

Psychotic depression, also known as depressive psychosis, is a major depressive episode that is accompanied by psychotic symptoms. It can occur in the context of bipolar disorder or major depressive disorder. It can be difficult to distinguish from schizoaffective disorder, a diagnosis that requires the presence of psychotic symptoms for at least two weeks without any mood symptoms present. Unipolar psychotic depression requires that psychotic symptoms occur during severe depressive episodes, although residual psychotic symptoms may also be present in between episodes. Diagnosis using the DSM-5 involves meeting the criteria for a major depressive episode, along with the criteria for "mood-congruent or mood-incongruent psychotic features" specifier.

Akinetic mutism is a medical condition where patients tend neither to move (akinesia) nor speak (mutism). Akinetic mutism was first described in 1941 as a mental state where patients lack the ability to move or speak. However, their eyes may follow their observer or be diverted by sound. Patients lack most motor functions such as speech, facial expressions, and gestures, but demonstrate apparent alertness. They exhibit reduced activity and slowness, and can speak in whispered monosyllables. Patients often show visual fixation on their examiner, move their eyes in response to an auditory stimulus, or move after often repeated commands. Patients with akinetic mutism are not paralyzed, but lack the will to move. Many patients describe that as soon as they "will" or attempt a movement, a "counter-will" or "resistance" rises up to meet them.

Oneiroid syndrome (OS) is a condition involving dream-like disturbances of one's consciousness by vivid scenic hallucinations, accompanied by catatonic symptoms (either catatonic stupor or excitement), delusions, or psychopathological experiences of a kaleidoscopic nature. The term is from Ancient Greek "ὄνειρος" (óneiros, meaning "dream") and "εἶδος" (eîdos, meaning "form, likeness"; literally dream-like / oneiric or oniric, sometimes called "nightmare-like"). It is a common complication of catatonic schizophrenia, although it can also be caused by other mental disorders. The dream-like experiences are vivid enough to seem real to the patient. OS is distinguished from delirium by the fact that the imaginative experiences of patients always have an internal projection. This syndrome is hardly mentioned in standard psychiatric textbooks, possibly because it is not listed in DSM.

<span class="mw-page-title-main">Waxy flexibility</span> Catatonia psychomotor symptom

Waxy flexibility is one of the twelve symptoms that can lead to the diagnosis of catatonia. It is a psychomotor symptom that results in a decreased response to stimuli and a tendency to remain in an immobile posture. If one were to move the arm of someone with waxy flexibility, the patient would keep that arm where it had been positioned until moved again as if positioning malleable wax. Attempts to reposition the patient are met by "slight, even resistance".

<span class="mw-page-title-main">Benzodiazepine withdrawal syndrome</span> Signs and symptoms due to benzodiazepines discontinuation in physically dependent persons

Benzodiazepine withdrawal syndrome is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.

The management of schizophrenia usually involves many aspects including psychological, pharmacological, social, educational, and employment-related interventions directed to recovery, and reducing the impact of schizophrenia on quality of life, social functioning, and longevity.

<span class="mw-page-title-main">Postpartum psychosis</span> Rare psychiatric emergency beginning suddenly in the first two weeks after childbirth

Postpartum psychosis (PPP), also known as puerperal psychosis or peripartum psychosis, involves the abrupt onset of psychotic symptoms shortly following childbirth, typically within two weeks of delivery but less than 4 weeks postpartum. PPP is a condition currently represented under "Brief Psychotic Disorder" in the Diagnostic and Statistical Manual of Mental Disorders, Volume V (DSM-V). Symptoms may include delusions, hallucinations, disorganized speech, and/or abnormal motor behavior. Other symptoms frequently associated with PPP include confusion, disorganized thought, severe difficulty sleeping, variations of mood disorders, as well as cognitive features such as consciousness that comes and goes or disorientation.

Childhood schizophrenia is similar in characteristics of schizophrenia that develops at a later age, but has an onset before the age of 13 years, and is more difficult to diagnose. Schizophrenia is characterized by positive symptoms that can include hallucinations, delusions, and disorganized speech; negative symptoms, such as blunted affect and avolition and apathy, and a number of cognitive impairments. Differential diagnosis is problematic since several other neurodevelopmental disorders, including autism spectrum disorder, language disorder, and attention deficit hyperactivity disorder, also have signs and symptoms similar to childhood-onset schizophrenia.

The diagnosis of schizophrenia, a psychotic disorder, is based on criteria in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, or the World Health Organization's International Classification of Diseases (ICD). Clinical assessment of schizophrenia is carried out by a mental health professional based on observed behavior, reported experiences, and reports of others familiar with the person. Diagnosis is usually made by a psychiatrist. Associated symptoms occur along a continuum in the population and must reach a certain severity and level of impairment before a diagnosis is made. Schizophrenia has a prevalence rate of 0.3-0.7% in the United States.

Autistic catatonia is a term used to describe the occurrence of catatonia in autistic people. Catatonia occurs in roughly 10 percent of people diagnosed with an autism spectrum disorder. In addition to the common sign of catatonia, autistic people with catatonia are more likely to stim and self-harm.

<span class="mw-page-title-main">Bell's mania</span> Medical condition

Bell's mania, also known as delirious mania, refers to an acute neurobehavioral syndrome. This is usually characterized by an expeditious onset of delirium, mania, psychosis, followed by grandiosity, emotional lability, altered consciousness, hyperthermia, and in extreme cases, death. It is sometimes misdiagnosed as excited delirium (EXD) or catatonia due to the presence of overlapping symptoms. Pathophysiology studies reveal elevated dopamine levels in the neural circuit as the underlying mechanism. Psychostimulant users as well as individuals experiencing severe manic episodes are more prone to the manifestation of this condition. Management solutions such as sedation and ketamine injections have been discussed for medical professionals and individuals with the condition. Bell's mania cases are commonly reported in countries like the United States and Canada and are commonly associated with psychostimulant use and abuse.

References

  1. 1 2 3 Balaguer AP, Rivero IS (22 December 2021). "Electroconvulsive therapy, catatonia, deep vein thrombosis and anticoagulant treatment: a case report". General Psychiatry. 34 (6): e100666. doi:10.1136/gpsych-2021-100666. ISSN   2517-729X. PMC   8705197 . PMID   35028525.
  2. 1 2 3 4 Fink M, Taylor MA (1 November 2009). "The Catatonia Syndrome: Forgotten but Not Gone". Archives of General Psychiatry. 66 (11): 1173–1177. doi:10.1001/archgenpsychiatry.2009.141. PMID   19884605.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Burrow JP, Spurling BC, Marwaha R (2022). "Catatonia". StatPearls. StatPearls Publishing. PMID   28613592.
  4. Fink M (2011). "Catatonia from its creation to DSM-V: Considerations for ICD". Indian Journal of Psychiatry. 53 (3): 214–217. doi: 10.4103/0019-5545.86810 . PMC   3221176 . PMID   22135438.
  5. Fink M (July 2009). "Catatonia: A Syndrome Appears, Disappears, and is Rediscovered". The Canadian Journal of Psychiatry. 54 (7): 437–445. doi: 10.1177/070674370905400704 . PMID   19660165.
  6. 1 2 Carroll BT, Goforth HW, Thomas C, Ahuja N, McDaniel WW, Kraus MF, Spiegel DR, Franco KN, Pozuelo L, Muñoz C (October 2007). "Review of Adjunctive Glutamate Antagonist Therapy in the Treatment of Catatonic Syndromes". The Journal of Neuropsychiatry and Clinical Neurosciences. 19 (4): 406–412. doi:10.1176/jnp.2007.19.4.406. PMID   18070843.
  7. 1 2 3 4 Fink M, Taylor MA (2003). Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press. ISBN   978-0-521-82226-8.[ page needed ]
  8. 1 2 3 4 5 6 7 8 Heckers S, Walther S (9 November 2023). "Catatonia". New England Journal of Medicine. 389 (19): 1797–1802. doi:10.1056/NEJMra2116304. PMID   37937779. S2CID   265673511.
  9. Zisselman MH, Jaffe RL (February 2010). "ECT in the Treatment of a Patient With Catatonia: Consent and Complications". American Journal of Psychiatry. 167 (2): 127–132. doi:10.1176/appi.ajp.2009.09050703. PMID   20123920.
  10. 1 2 3 4 5 6 Rasmussen SA, Mazurek MF, Rosebush PI (2016). "Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology". World Journal of Psychiatry. 6 (4): 391–398. doi: 10.5498/wjp.v6.i4.391 . PMC   5183991 . PMID   28078203.
  11. Shorter E, Fink M (2018). The Madness of Fear: A History of Catatonia. Oxford University Press. ISBN   978-0-19-088119-1.
  12. Nolen-Hoeksema S (2014). Abnormal Psychology. McGraw-Hill Education. p. 224. ISBN   978-1-259-06072-4.
  13. 1 2 3 "Cercle d'excellence sur les Psychoses: Introduction". www.cercle-d-excellence-psy.org. Retrieved 25 May 2022.[ permanent dead link ]
  14. 1 2 Gazdag G, Takács R, Ungvari GS (22 September 2017). "Catatonia as a putative nosological entity: A historical sketch". World Journal of Psychiatry. 7 (3): 177–183. doi: 10.5498/wjp.v7.i3.177 . PMC   5632602 . PMID   29043155.
  15. Ghaziuddin M (28 October 2021). "Catatonia: A Common Cause of Late Regression in Autism". Frontiers in Psychiatry. 12: 674009. doi: 10.3389/fpsyt.2021.674009 . PMC   8585308 . PMID   34777033.
  16. 1 2 Vaquerizo-Serrano J, Salazar De Pablo G, Singh J, Santosh P (2022). "Catatonia in autism spectrum disorders: A systematic review and meta-analysis". European Psychiatry. 65 (1): e4. doi:10.1192/j.eurpsy.2021.2259. PMC   8792870 . PMID   34906264.
  17. 1 2 3 4 Serra-Mestres J, Jaimes-Albornoz W (29 June 2018). "Recognizing Catatonia in Medically Hospitalized Older Adults: Why It Matters". Geriatrics. 3 (3): 37. doi: 10.3390/geriatrics3030037 . PMC   6319219 . PMID   31011075.
  18. Dhossche DM, Rout U (2006). "Are Autistic and Catatonic Regression Related? A Few Working Hypotheses Involving Gaba, Purkinje Cell Survival, Neurogenesis, and ECT". International Review of Neurobiology. Vol. 72. pp. 55–79. doi:10.1016/S0074-7742(05)72004-3. ISBN   978-0-12-366873-8. PMID   16697291.
  19. Arieti S (1994). Interpretation of schizophrenia. Jason Aronson. ISBN   1-56821-209-7. OCLC   472906047.
  20. Rogers JP, Pollak TA, Blackman G, David AS (July 2019). "Catatonia and the immune system: a review". The Lancet Psychiatry. 6 (7): 620–630. doi:10.1016/S2215-0366(19)30190-7. PMC   7185541 . PMID   31196793.
  21. Haroche A, Rogers J, Plaze M, Gaillard R, Williams SC, Thomas P, Amad A (July 2020). "Brain imaging in catatonia: systematic review and directions for future research". Psychological Medicine. 50 (10): 1585–1597. doi:10.1017/S0033291720001853. PMID   32539902. S2CID   219704600.
  22. Geoffroy PA, Rolland B, Cottencin O (1 May 2012). "Catatonia and Alcohol Withdrawal: A Complex and Underestimated Syndrome". Alcohol and Alcoholism. 47 (3): 288–290. doi: 10.1093/alcalc/agr170 . PMID   22278315.
  23. Rosebush PI, Mazurek MF (August 1996). "Catatonia after benzodiazepine withdrawal". Journal of Clinical Psychopharmacology. 16 (4): 315–319. doi:10.1097/00004714-199608000-00007. PMID   8835707.
  24. Deuschle M, Lederbogen F (January 2001). "Benzodiazepine withdrawal-induced catatonia". Pharmacopsychiatry. 34 (1): 41–42. doi:10.1055/s-2001-15188. PMID   11229621. S2CID   260241781.
  25. Kanemoto K, Miyamoto T, Abe R (September 1999). "Ictal catatonia as a manifestation of de novo absence status epilepticus following benzodiazepine withdrawal". Seizure. 8 (6): 364–366. doi: 10.1053/seiz.1999.0309 . PMID   10512781. S2CID   17454162.
  26. 1 2 American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing. pp.  119–121. ISBN   978-0-89042-555-8.
  27. Walther S, Stegmayer K, Wilson JE, Heckers S (July 2019). "Structure and neural mechanisms of catatonia". The Lancet Psychiatry. 6 (7): 610–619. doi:10.1016/S2215-0366(18)30474-7. PMC   6790975 . PMID   31196794.
  28. Dhossche DM, Stoppelbein L, Rout UK (December 2010). "Etiopathogenesis of Catatonia: Generalizations and Working Hypotheses". The Journal of ECT. 26 (4): 253–258. doi:10.1097/YCT.0b013e3181fbf96d. PMID   21076339.
  29. Northoff G (July 2000). "Brain Imaging in Catatonia: Current Findings and a Pathophysiologic Model". CNS Spectrums. 5 (7): 34–46. doi:10.1017/s1092852900013377. PMID   18197154. S2CID   12837559.
  30. Northoff G (October 2002). "What catatonia can tell us about 'top-down modulation': A neuropsychiatric hypothesis". Behavioral and Brain Sciences. 25 (5): 555–577. doi:10.1017/s0140525x02000109. PMID   12958742. S2CID   20407002.
  31. Fink M (2003). Catatonia : a clinician's guide to diagnosis and treatment. Michael Alan Taylor. Cambridge: Cambridge University Press. ISBN   0-511-06198-6. OCLC   57254202.[ page needed ]
  32. 1 2 3 4 5 6 7 8 9 American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. Washington, DC: American Psychiatric Association. doi:10.1176/appi.books.9780890425787. ISBN   978-0-89042-575-6. S2CID   249488050.
  33. Jeste DV, Lieberman JA, Benson RS, Young ML, Akaka J, Bernstein CA, Crowley B, Everett AS, Geller J, Graff MD, Greene JA, Kashtan JF, Mcvoy MK, Nininger JE, Oldham JM, Schatzberg AF, Widge AS, Vanderlip ER (2013). Diagnostic and Statistical Manual of Mental Disorders Fifth Edition DSM-5TM. American Psychiatric Association . Retrieved 8 December 2023.
  34. Michael B. First (2013). DSM-5® Handbook of Differential Diagnosis. American Psychiatric Publishing. p. 49. ISBN   978-1-58562-998-5.
  35. Sienaert P, Rooseleer J, De Fruyt J (December 2011). "Measuring catatonia: A systematic review of rating scales". Journal of Affective Disorders. 135 (1–3): 1–9. doi:10.1016/j.jad.2011.02.012. PMID   21420736.
  36. Bush G, Fink M, Petrides G, Dowling F, Francis A (February 1996). "Catatonia. I. Rating scale and standardized examination". Acta Psychiatrica Scandinavica. 93 (2): 129–136. doi:10.1111/j.1600-0447.1996.tb09814.x. PMID   8686483. S2CID   20752576.
  37. 1 2 3 Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G (9 December 2014). "A Clinical Review of the Treatment of Catatonia". Frontiers in Psychiatry. 5: 181. doi: 10.3389/fpsyt.2014.00181 . PMC   4260674 . PMID   25538636.
  38. "Catatonia in French Psychiatry: Implications of the Zolpidem Challenge Test". Psychiatric Annals. 37 (1): 00485713–20070101–02. January 2007. doi:10.3928/00485713-20070101-02.
  39. 1 2 Simon LV, Hashmi MF, Callahan AL (2022). "Neuroleptic Malignant Syndrome". StatPearls. StatPearls Publishing. PMID   29489248.
  40. Northoff G (1 December 2002). "Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology". Journal of Neural Transmission. 109 (12): 1453–1467. CiteSeerX   10.1.1.464.9266 . doi:10.1007/s00702-002-0762-z. PMID   12486486. S2CID   12971112.
  41. 1 2 Samanta D, Lui F (2022). "Anti-NMDA Receptor Encephalitis". StatPearls. StatPearls Publishing. PMID   31869136.
  42. Foong AL, Grindrod KA, Patel T, Kellar J (October 2018). "Demystifying serotonin syndrome (or serotonin toxicity)". Canadian Family Physician. 64 (10): 720–727. PMC   6184959 . PMID   30315014.
  43. Watt S, McAllister RK (2022). "Malignant Hyperthermia". StatPearls. StatPearls Publishing. PMID   28613578.
  44. Arnts H, van Erp WS, Lavrijsen JC, van Gaal S, Groenewegen HJ, van den Munckhof P (May 2020). "On the pathophysiology and treatment of akinetic mutism". Neuroscience & Biobehavioral Reviews. 112: 270–278. doi: 10.1016/j.neubiorev.2020.02.006 . hdl: 11245.1/c438b878-4d5b-4f13-887c-7f01df095324 . PMID   32044373.
  45. Ackermann H, Ziegler W (February 1995). "Akinetischer Mutismus – eine Literaturübersicht". Fortschritte der Neurologie · Psychiatrie. 63 (2): 59–67. doi:10.1055/s-2007-996603. PMID   7705740. S2CID   260156218.
  46. Holka-Pokorska J, Piróg-Balcerzak A, Jarema M (30 April 2018). "The controversy around the diagnosis of selective mutism – a critical analysis of three cases in the light of modern research and diagnostic criteria". Psychiatria Polska. 52 (2): 323–343. doi: 10.12740/PP/76088 . PMID   29975370.
  47. Wylie T, Sandhu DS, Murr N (2022). "Status Epilepticus". StatPearls. StatPearls Publishing. PMID   28613459.
  48. Sutter R, Kaplan PW (August 2012). "Electroencephalographic criteria for nonconvulsive status epilepticus: Synopsis and comprehensive survey: EEG Criteria for NCSE". Epilepsia. 53: 1–51. doi:10.1111/j.1528-1167.2012.03593.x. PMID   22862158. S2CID   24014621.
  49. Delirium: prevention, diagnosis and management. National Institute for Health and Care Excellence: Guidelines. National Institute for Health and Care Excellence (NICE). 2019. ISBN   978-1-4731-2992-4. PMID   31971702.
  50. M Das J, Anosike K, Asuncion RM (2022). "Locked-in Syndrome". StatPearls. StatPearls Publishing. PMID   32644452.
  51. Balint B, Meinck HM (July 2018). "Pragmatic Treatment of Stiff Person Spectrum Disorders: Pragmatic Treatment of SPSD". Movement Disorders Clinical Practice. 5 (4): 394–401. doi:10.1002/mdc3.12629. PMC   6174384 . PMID   30363317.
  52. Baizabal-Carvallo JF, Jankovic J (August 2015). "Stiff-person syndrome: insights into a complex autoimmune disorder". Journal of Neurology, Neurosurgery & Psychiatry. 86 (8): 840–848. doi:10.1136/jnnp-2014-309201. PMID   25511790. S2CID   19981869.
  53. Sarva H, Deik A, Ullah A, Severt WL (4 March 2016). "Clinical Spectrum of Stiff Person Syndrome: A Review of Recent Reports". Tremor and Other Hyperkinetic Movements. 6: 340. doi:10.7916/D85M65GD. PMC   4790195 . PMID   26989571.
  54. Rasmussen SA, Mazurek MF, Rosebush PI (2016). "Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology". World Journal of Psychiatry. 6 (4): 1875–1879. doi: 10.5498/wjp.v6.i4.391 . PMC   5183991 . PMID   8078203.
  55. Thenganatt M, Jankovic J (2016). "Psychogenic (Functional) parkinsonism". Functional Neurologic Disorders. Handbook of Clinical Neurology. Vol. 139. pp. 259–262. doi:10.1016/B978-0-12-801772-2.00022-9. ISBN   978-0-12-801772-2. PMID   27719845.
  56. Ganos C, Kassavetis P, Cerdan M, Erro R, Balint B, Price G, Edwards MJ, Bhatia KP (June 2015). "Revisiting the Syndrome of "Obsessional Slowness"". Movement Disorders Clinical Practice. 2 (2): 163–169. doi:10.1002/mdc3.12140. PMC   6353487 . PMID   30713890. S2CID   73414098.
  57. Rosso M, Fremion E, Santoro SL, Oreskovic NM, Chitnis T, Skotko BG, Santoro JD (2020). "Down Syndrome Disintegrative Disorder: A Clinical Regression Syndrome of Increasing Importance". Pediatrics. 145 (6): e20192939. doi: 10.1542/peds.2019-2939 . PMID   32471843. S2CID   219104019.
  58. https://adscresources.advocatehealth.com/resources/obsessional-slowness/#:~:text=The%20persistent%20stress%20of%20the%20rapidly%20moving%20environment,slowness%2C%20which%20we%20have%20also%20labeled%20%E2%80%9CThe%20Pace.%E2%80%9D; retrieved 2023 Aug 18
  59. Lyons A, Allen NM, Flanagan O, Cahalane D (2020). "Catatonia as a feature of down syndrome: An under-recognised entity?". European Journal of Paediatric Neurology. 25: 187–190. doi: 10.1016/j.ejpn.2020.01.005 . PMID   31959555. S2CID   210841869.
  60. Daniels J (October 2009). "Catatonia: Clinical Aspects and Neurobiological Correlates". The Journal of Neuropsychiatry and Clinical Neurosciences. 21 (4): 371–380. doi:10.1176/jnp.2009.21.4.371. PMID   19996245.
  61. Leroy A, Naudet F, Vaiva G, Francis A, Thomas P, Amad A (October 2018). "Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis". European Archives of Psychiatry and Clinical Neuroscience. 268 (7): 675–687. doi:10.1007/s00406-017-0819-5. PMID   28639007. S2CID   4013882.
  62. 1 2 Saini A, Begum N, Matti J, Ghanem DA, Fripp L, Pollak TA, Zandi MS, David A, Lewis G, Rogers J (15 September 2022). "Clozapine as a treatment for catatonia: A systematic review" (PDF). Schizophrenia Research. 263: 275–281. doi: 10.1016/j.schres.2022.09.021 . ISSN   0920-9964. PMID   36117082. S2CID   252276294.
  63. American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders. doi:10.1176/appi.books.9780890425787. ISBN   978-0-89042-578-7. S2CID   249488050.[ page needed ]
  64. Solmi M, Pigato GG, Roiter B, Guaglianone A, Martini L, Fornaro M, Monaco F, Carvalho AF, Stubbs B, Veronese N, Correll CU (20 August 2018). "Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis". Schizophrenia Bulletin. 44 (5): 1133–1150. doi:10.1093/schbul/sbx157. PMC   6101628 . PMID   29140521.
  65. 1 2 Rogers JP, Pollak TA, Begum N, Griffin A, Carter B, Pritchard M, Broadbent M, Kolliakou A, Ke J, Stewart R, Patel R, Bomford A, Amad A, Zandi MS, Lewis G, Nicholson TR, David AS (2 November 2021). "Catatonia: demographic, clinical and laboratory associations". Psychological Medicine. 53 (6): 2492–2502. doi: 10.1017/S0033291721004402 . PMC   10123832 . PMID   35135642. S2CID   242076501.
  66. Parsanoglu Z, Balaban OD, Gica S, Atay OC, Altin O (May 2022). "Comparison of the Clinical and Treatment Characteristics of Patients Undergoing Electroconvulsive Therapy for Catatonia Indication in the Context of Gender". Clinical EEG and Neuroscience. 53 (3): 175–183. doi:10.1177/15500594211025889. PMID   34142904. S2CID   235471133.
  67. Berrios GE (1981). "Stupor: A conceptual history". Psychological Medicine. 11 (4): 677–688. doi:10.1017/s0033291700041179. PMID   7034030. S2CID   26932116.
  68. Berrios GE, Marková IS (2018). "Historical and conceptual aspects of motor disorders in the psychoses". Schizophrenia Research. 200: 5–11. doi:10.1016/j.schres.2017.09.008. PMID   28941779. S2CID   26892840.
  69. "Zur Entwicklung der Psychiatrie - ein Internet-Atlas von Dr. Hans-Peter Haack" (in German). Archived from the original on 9 February 2008. Retrieved 29 June 2017.